The ExoFLARE™ exosome tracking assay allows for the detection and monitoring of exosomes in vitro and in vivo.
The ExoFLARE™ exosome tracking assay utilizes a combination of a FLARE (fluorescence activating response element) protein tag linked via a transmembrane domain to the individual tetraspanin proteins CD9, CD63, and CD81, together with a pro-fluorophore dye.
Neither the protein nor the dye fluoresce in isolation; fluorescence is only achieved when the protein binds to the dye. The protein and pro-fluorophore dye form an unstable bond with a continuous turnover of the dye, which causes a change in the chemical structure, resulting in fluorescence. The continuous turnover allows for sustained fluorescence without the levels of photo-bleaching commonly associated with fluorescent proteins.
The ExoFLARE™ assay can be monitored for extensive periods for tracking of the dye’s movement.
TRIFic™ technology: exosome detection
The TRIFic™ exosome detection assay is an ELISA-like assay in the sense that it is an antibody sandwich-based assay for the detection of exosome particles. However, there are some significant differences. Unlike a standard ELISA assay, there is no enzymatic reaction. Rather, the exosome target is detected directly with a Europium labelled-antibody, constituting a time-resolved immunofluorescence assay.
The TRIFic™ exosome assays provide clear and consistent data quickly from purified or unpurified samples in a convenient 96-well format. The kit is available for marker proteins CD9, CD63, and CD81.
NTA size profiling service
Nanoparticle tracking analysis (NTA) is a technique used for the simultaneous measurement and analysis of the size and concentration of single nanoparticles with high precision, accuracy, and reproducibility.
The NTA service is performed in our laboratories by a team of experienced scientists. All data and selected parameters are provided as a final report. We use the ZetaView® nanoparticle analysis instrument.
Exosome validated antibodies
The exosome marker antibodies have been validated against exosome-associated antigens CD9, CD63, and CD81 to characterize and/or quantify exosomes in cell culture media and biological fluids. The high-quality exosome validated antibodies have been specifically tested for western blotting, the most common method to assess the presence of proteins in EV samples.